|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome** | **All patients** | **Patients with progressive lesions at TP1** | | |
|  |  | **Pseudo-**  **progression**  **only**  **(PP-only)** | **True progression only**  **(TPD-only)** | **Mixed pseudo-**  **progression and true progression**  **(PP&TPD)** |
| Total (N, %) | 112 (100%) | 9 (8%) | 16 (14%) | 11 (10%) |
| Median OS (months) | NR\* (30 - NR) | 30 (27 - NR) | 9 (7 - 18) | 25 (11 - NR) |
| Median PFS (months) | 6 (3 - 10) | 2 (1 - NR) | 2\*\* | 2 (2 - 4) |
| Median iPFS (months) | 16 (8 - 33) | NR (1 - NR) | 2 (2 - 4) | 2 (2 - 4) |
| 2-year OS (%) | 69% (58% - 77%) | 100%\*\* | 14% (2% - 36%) | 53% (21% - 77%) |
| 2-year PFS (%) | 24% (16% - 33%) | 30% (5% - 61%) | 0%\*\* | 0%\*\* |
| 2-year iPFS (%) | 42% (32% - 51%) | 53% (18% - 80%) | 6% (0% - 25%) | 0%\*\* |

\*NR - not reached  
\*\* 95% confidence intervals could not be estimated

**Table S3. Summary of patient outcome of the individual groups (without landmark analysis)** 95% confidence intervals were provided in parentheses.PP-only patients were the best performing group, with a similar outcome compared to responding patients. TPD-only patients presented a significantly worse OS of 9 vs. 30 months in the PP-only group (p=0.001, FWER=0.007). Patients with mixed PP&TPD were in between both other groups.